Key Points
- CEO August Troendle sold 673 Medpace shares at an average price of $620.38, generating approximately $417,516; he retained 544,544 shares worth about $337.8 million.
- Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 versus a $3.98 consensus estimate and revenue of $707.33 million, up 17.2% year over year.
- Analysts maintain a consensus “Hold” rating, with an average price target of $584.18, below the stock’s $611.57 opening price; institutional investors own nearly 78% of shares.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 673 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $620.38, for a total transaction of $417,515.74. Following the completion of the transaction, the chief executive officer directly owned 544,544 shares of the company's stock, valued at approximately $337,824,206.72. The trade was a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Medpace Price Performance
Shares of MEDP opened at $611.57 on Friday. The company has a 50-day simple moving average of $562.52 and a two-hundred day simple moving average of $493.80. The firm has a market capitalization of $17.07 billion, a PE ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the business earned $3.10 EPS. The business's revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Institutional Trading of Medpace
Several institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC increased its stake in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock worth $24,929,000 after buying an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Medpace in the second quarter worth approximately $296,000. Finally, M&T Bank Corp grew its holdings in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after buying an additional 31 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on MEDP shares. Mizuho upped their price target on Medpace from $586.00 to $665.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Weiss Ratings raised Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a report on Friday, July 24th. Robert W. Baird upped their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and an average target price of $584.18.
Read Our Latest Stock Report on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
